[PDF][PDF] Anogenital human papillomavirus prevalence is unaffected by therapeutic tumour necrosis factor-alpha inhibition.
A Handisurya, S Lázár, P Papay, C Primas… - Acta Dermato …, 2016 - researchgate.net
METHODS This prospective, open, controlled observation study with crosssectional analysis
was approved by the Institutional Review Board of the Medical University of Vienna …
was approved by the Institutional Review Board of the Medical University of Vienna …
Anogenital human papillomavirus prevalence is unaffected by therapeutic tumour necrosis factor-alpha inhibition.
A Handisurya, S Lázár, P Papay, C Primas, A Haitel… - 2016 - cabidigitallibrary.org
Patients receiving tumour necrosis factor alpha (TNF-α) inhibitors are at increased risk of
exacerbation of (myco-) bacterial and some viral infections. However, information on …
exacerbation of (myco-) bacterial and some viral infections. However, information on …
Anogenital Human Papillomavirus Prevalence is Unaffected by Therapeutic Tumour Necrosis Factor-alpha Inhibition.
A Handisurya, S Lázár, P Papay, C Primas… - Acta Dermato …, 2016 - europepmc.org
Patients receiving tumour necrosis factor alpha (TNF-α) inhibitors are at increased risk of
exacerbation of (myco-) bacterial and some viral infections. However, information on …
exacerbation of (myco-) bacterial and some viral infections. However, information on …
Anogenital Human Papillomavirus Prevalence is Unaffected by Therapeutic Tumour Necrosis Factor-alpha Inhibition.
A HANDISURYA, S LÁZÁR, P PAPAY… - Acta Dermato …, 2016 - search.ebscohost.com
Patients receiving tumour necrosis factor alpha (TNF-α) inhibitors are at increased risk of
exacerbation of (myco-) bacterial and some viral infections. However, information on …
exacerbation of (myco-) bacterial and some viral infections. However, information on …
Anogenital Human Papillomavirus Prevalence is Unaffected by Therapeutic Tumour Necrosis Factor-alpha Inhibition
A Handisurya, S Lázár, P Papay… - Acta Dermato …, 2016 - medicaljournalssweden.se
Patients receiving tumour necrosis factor alpha (TNF-α) inhibitors are at increased risk of
exacerbation of (myco-) bacterial and some viral infections. However, information on …
exacerbation of (myco-) bacterial and some viral infections. However, information on …
Anogenital Human Papillomavirus Prevalence is Unaffected by Therapeutic Tumour Necrosis Factor-alpha Inhibition
A Handisurya, S Lázár, P Papay… - Acta dermato …, 2016 - pubmed.ncbi.nlm.nih.gov
Patients receiving tumour necrosis factor alpha (TNF-α) inhibitors are at increased risk of
exacerbation of (myco-) bacterial and some viral infections. However, information on …
exacerbation of (myco-) bacterial and some viral infections. However, information on …